Sinocare Inc

Chart & Performance

D1W1MN

P/E

29.32

P/S

2.15

EPS

0.59

Div Yield, %

1.15%

Shrs. gr., 5y

-0.15%

Rev. gr., 5y

20.10%

Revenues

4.44b

+9.47%

Net income

326m

+14.73%

CFO

631m

-14.13%

Dividend

Jun 17, 20240.2 CNY/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Sinocare Inc. engages in the development, manufacture, and marketing of diagnosis rapid testing products primarily in the People's Republic of China. It offers SARS-CoV-2 antibody test strip; Safe-Accu blood glucose monitoring systems; Safe-AQ blood glucose monitoring systems; Gold-Accu blood glucose monitoring systems; Safe-Accu UG blood, glucose, and uric acid monitoring systems; Safe-Accu KG blood, glucose, and ketone monitoring systems; and D Nurse mobile glucose meters. The company provides its products for the patients with chronic diseases and diabetes, as well as for healthcare professionals. It also exports its products to 135 countries. Sinocare Inc. was founded in 2002 and is based in Changsha, the People's Republic of China.

URL

https://www.sinocare.com/

IPO date

Mar 19, 2012

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT